Immunome, Inc. (IMNM) Return on equity 2023–2025
Immunome, Inc. (IMNM) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-33.5%FY2025 · since FY2023: -89.1% → -33.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -33.5% | +128.2 pp |
| FY2024 | -161.7% | -72.6 pp |
| FY2023 | -89.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More IMNM financial trends
IMNM RevenueIMNM Net incomeIMNM Net marginIMNM Gross profitIMNM Gross marginIMNM Operating incomeIMNM Operating marginIMNM Operating cash flowIMNM Free cash flowIMNM Capital expendituresIMNM Stock buybacksIMNM Dividends paidIMNM Total assetsIMNM Total liabilitiesIMNM Shareholders’ equityIMNM overview →